Remicade (infliximab) is effective for controlling inflammatory conditions like Crohn’s disease, ulcerative colitis, and rheumatoid arthritis, but staying on it for years introduces a distinct set of risks that differ from the short-term side effects you hear about early on. The concerns range from gradually rising infection susceptibility and cancer risk to subtler problems like your body developing antibodies against the drug itself. None of these mean you should panic, but they do mean long-term Remicade use requires ongoing monitoring that evolves over time.
Serious Infections and Tuberculosis
Remicade works by blocking tumor necrosis factor-alpha (TNF-alpha), a signaling molecule your immune system relies on to fight infections. That suppression is exactly what calms down autoimmune inflammation, but it also leaves you more vulnerable to infections that a healthy immune system would normally contain. The longer you stay on the drug, the longer that vulnerability persists.
Tuberculosis is the most well-documented infectious risk. Early post-marketing surveillance revealed that Remicade could reactivate latent TB infections that had been dormant for years or decades. Many of the initial reported cases involved extrapulmonary or disseminated TB, forms that are unusual in the general population and pointed clearly to the drug’s immune-suppressing effects.1PubMed. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent This is why every patient must be screened for latent TB before starting Remicade, and why periodic re-screening makes sense if you travel to high-risk areas or have ongoing exposure.
Beyond TB, opportunistic fungal infections like histoplasmosis and other atypical infections can emerge during long-term treatment. The practical takeaway is straightforward: fevers, persistent coughs, unexplained weight loss, and night sweats deserve prompt medical attention when you are on Remicade. These symptoms would warrant a visit for anyone, but the threshold for concern should be lower when your TNF signaling is being deliberately suppressed.
Hepatitis B Reactivation
If you carry hepatitis B, even if it has been inactive for years, Remicade can trigger a severe reactivation. In a study of Crohn’s disease patients with chronic hepatitis B, two out of three who received infliximab experienced severe viral reactivation after the drug was withdrawn, and one of those patients died.2PubMed Central. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis The reactivation can occur during treatment or, as those cases showed, after stopping the drug. Screening for hepatitis B before starting therapy is now standard practice, and patients who test positive typically need antiviral prophylaxis running concurrently with Remicade.
Cancer Risks Over Time
Cancer risk is probably the concern that weighs most heavily on people considering long-term Remicade. The relationship between TNF-alpha blockers and malignancy is genuinely complicated, because the inflammatory diseases Remicade treats also carry their own elevated cancer risks. Disentangling the drug’s contribution from the disease’s contribution is something researchers have wrestled with for over two decades.
That said, some signals are consistent. A large retrospective study of patients with psoriasis and rheumatoid arthritis found that long-term infliximab use was associated with roughly two-and-a-half times the risk of lymphoma compared to non-users, an association that held up after statistical adjustments for confounding factors.3Scientific Reports. Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study Lymphoma is already more common in people with chronic inflammatory conditions, so Remicade may be amplifying an existing vulnerability rather than creating a new one from scratch. But the added risk is real and merits regular follow-up.
Skin Cancer
Skin cancer is another area where the evidence has firmed up over the years. A study of inflammatory bowel disease patients found that long-term users of anti-TNF drugs had roughly four times the odds of melanoma compared to patients who were not using these drugs long-term.4PubMed Central. Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease That is a meaningful increase. Annual dermatologic screenings are recommended for anyone on long-term Remicade, and being diligent about sun protection matters more than it does for the general population.
Hepatosplenic T-Cell Lymphoma
One rare but alarming cancer linked to Remicade is hepatosplenic T-cell lymphoma (HSTCL), an aggressive and often fatal malignancy. Early FDA reports identified eight cases in young patients with inflammatory bowel disease who were on infliximab, six of which were fatal. All eight were also taking another immunosuppressant like azathioprine at the same time.5PubMed. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease A systematic review confirmed that the combination of anti-TNF drugs with thiopurines is the common thread in most HSTCL cases.6Clinical Gastroenterology and Hepatology. A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease The risk appears concentrated in young men on combination therapy, and while the absolute number of cases is very small, the severity has shaped prescribing decisions. Many gastroenterologists now weigh the benefits of combination therapy more carefully in younger patients and consider monotherapy strategies where possible.
Infusion Reactions and Loss of Response
One of the more frustrating long-term dynamics with Remicade is that your body can develop antibodies against the drug itself. In a study of Crohn’s disease patients, antibodies against infliximab were detected in about 60 percent of patients over time. Those with higher antibody concentrations before an infusion had responses that lasted only about half as long, and their risk of infusion reactions was more than doubled.7PubMed. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease
Infusion reactions can range from mild symptoms like flushing and headache to severe reactions including chest tightness, drops in blood pressure, and difficulty breathing. Even when reactions are not severe, they often serve as a warning sign that antibody levels are rising and that the drug is losing its effectiveness.8PubMed Central. Infliximab-Related Infusion Reactions: Systematic Review This is a key reason why many doctors combine Remicade with a low-dose immunomodulator like methotrexate or azathioprine: the companion drug suppresses antibody formation and helps maintain drug levels. It is also why monitoring drug trough levels and antibody concentrations has become routine practice during long-term treatment.
If you stop Remicade and later restart it, the antibody picture matters even more. Patients who had detectable antibodies at the time of re-treatment had roughly eight times the risk of an infusion reaction compared to those with undetectable antibodies.9PubMed. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy This is why drug holidays with Remicade are not as casual as they might be with other medications. If you stop and want to restart, your doctor will typically check antibody levels first to gauge the safety of re-treatment.
Drug-Induced Lupus and Autoimmune Reactions
Here is an irony that takes many patients by surprise: a drug designed to treat autoimmune disease can trigger new autoimmune phenomena. A large percentage of patients on Remicade develop antinuclear antibodies (ANA), the same markers associated with lupus. In studies, roughly half of Crohn’s disease patients and nearly two-thirds of rheumatoid arthritis patients treated with infliximab developed ANA positivity.10PubMed Central. A Case of Drug-Induced Lupus in Crohn’s Disease During Infliximab Therapy
Most of the time these antibodies are just a laboratory finding with no symptoms. But in a minority of cases, a full lupus-like syndrome develops, with inflammatory joint pain, skin rashes, and complement changes. Case reports describe patients who developed these symptoms months into treatment, with high titers of multiple autoantibodies and clinical features closely mimicking systemic lupus.11PubMed. A lupus-like syndrome associated with infliximab therapy The good news is that drug-induced lupus from Remicade generally resolves once the drug is discontinued, unlike true systemic lupus which is a lifelong condition. If you notice new joint pain, unexplained rashes, or unusual fatigue while on Remicade, it is worth raising with your doctor, because the overlap with your underlying disease symptoms can make this tricky to recognize.
Heart Failure and Cardiovascular Effects
TNF-alpha plays a role in cardiac function, and blocking it can occasionally cause problems you would not expect from an anti-inflammatory drug. Remicade carries a specific warning against use in patients with moderate-to-severe heart failure. Even in patients without pre-existing heart disease, cases of new-onset heart failure have been reported. One published case involved a patient who developed significant biventricular dysfunction six months after starting infliximab, with an ejection fraction that had dropped to 36 percent. The heart failure resolved after the drug was stopped.12PubMed Central. Heart failure as an adverse effect of infliximab for Crohn’s disease: A case report and review of the literature
Other cardiac effects have been reported on rare occasions, including rhythm disturbances and blood pressure drops during infusions. Close monitoring of heart function is recommended throughout treatment, and any new symptoms like shortness of breath, swelling in the legs, or unusual fatigue warrant cardiac evaluation.13PubMed Central. A rare case of supraventricular tachycardia induced by Infliximab: a case report
Neurological Complications
Among the rarer but more unsettling long-term risks are demyelinating disorders, conditions where the protective coating around nerve fibers in the brain or spinal cord breaks down. TNF-alpha blockers like Remicade have been linked to cases that closely resemble multiple sclerosis, even in patients with no prior neurological history.14Clinical Case Reports. Tumefactive Demyelinating Lesion Induced by Infliximab in a Patient With Rheumatoid Arthritis: A Case Report Some cases involve multifocal brain lesions that can be difficult to distinguish from MS on imaging.15BMC Neurology. Infliximab-associated multifocal central nervous system demyelination mimicking multiple sclerosis in a patient with Crohn’s disease: a case report
The mechanism is paradoxical. TNF-alpha normally plays a role in maintaining the myelin sheath and regulating immune cells in the nervous system. Blocking it can sometimes disrupt that balance in unpredictable ways. Symptoms to watch for include new visual disturbances, numbness or tingling in the limbs, difficulty with coordination, and cognitive changes. These events are uncommon, but if you have a personal or family history of MS or other demyelinating conditions, most doctors will avoid prescribing Remicade altogether.
Blood Cell Changes
Remicade has been associated with a range of blood cell abnormalities that can emerge over time. Post-marketing surveillance reports from Canada documented cases of low white blood cell counts, low platelet counts, and pancytopenia (where all major blood cell types drop), some of which were fatal.16PubMed Central. Infliximab and serious hematologic events These are uncommon but underscore why routine blood work is part of the monitoring schedule for long-term Remicade patients. If you notice unusual bruising, bleeding, persistent infections, or profound fatigue, these can be signs that your blood counts have shifted and need checking.
Pregnancy and Infant Drug Exposure
For women of childbearing age on long-term Remicade, pregnancy planning requires a conversation with your gastroenterologist or rheumatologist well in advance. Infliximab crosses the placenta, and cord blood levels at delivery are actually about double the mother’s blood levels. In a prospective study, the drug was still detectable in 93 percent of exposed infants at three months of age, about a quarter at six months, and a small percentage even at nine and twelve months.17Journal of Crohn’s and Colitis. Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children
The practical implication is that infants exposed to Remicade in utero need to delay live vaccines (such as rotavirus and BCG) until the drug has cleared from their system, typically at least six months after the last maternal dose. Many specialists aim to time the last Remicade infusion during pregnancy so that drug levels are as low as possible by delivery, though this has to be balanced against keeping the mother’s disease under control.
Surgical Complications
If you have Crohn’s disease and end up needing surgery while on Remicade, the timing of your last infusion matters. A meta-analysis covering over 2,500 patients found that receiving infliximab before surgery was associated with roughly 45 percent higher odds of postoperative complications overall, with both infectious and non-infectious complications increased.18PubMed. Preoperative infliximab use and postoperative complications in Crohn’s disease: a systematic review and meta-analysis A separate study confirmed that receiving infliximab within eight weeks of surgery was independently associated with higher rates of infectious complications.19PubMed. Compare risk factors associated with postoperative infectious complication in Crohn’s disease with and without preoperative infliximab therapy: a cohort study
This does not necessarily mean Remicade should always be stopped before planned surgery, because uncontrolled inflammation also impairs healing. But surgical teams generally want to know exactly when your last infusion was, and scheduling surgery at the end of a dosing interval when drug levels are at their lowest can help reduce wound complications.
Growth in Children With IBD
For pediatric patients, one consideration that extends beyond typical side-effect discussions is the relationship between Remicade and growth. Children with inflammatory bowel disease frequently have growth retardation driven by chronic inflammation and nutritional deficits. Getting inflammation under control with Remicade can improve growth, but the timing matters. Evidence suggests that treating inflammation with infliximab has limited benefit for catch-up growth once a child has reached late puberty.20Nature Reviews Gastroenterology & Hepatology. Growth problems in children with IBD This makes early intervention particularly important in pediatric patients, where the window for recovering lost growth potential narrows as puberty progresses.
Switching to a Biosimilar
If you have been on brand-name Remicade for years and your insurance or pharmacy switches you to a biosimilar version (such as CT-P13, marketed under names like Inflectra or Remsima), you may wonder whether the long-term side-effect profile changes. The NOR-SWITCH trial and its extension study followed patients who switched from originator infliximab to CT-P13 and found no differences in safety, efficacy, or rates of anti-drug antibody development between those who switched and those who stayed on the original.21Journal of Internal Medicine. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial Real-world follow-up data over two years showed that most patients who switched maintained good efficacy and safety profiles.22PubMed Central. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data A systematic review of switching studies across IBD populations reached the same conclusion: no unexpected or serious adverse events emerged after the switch, and outcomes were clinically equivalent.23PubMed. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease
The evidence here is actually reassuring and fairly robust. If your long-term side-effect concerns are specifically about the switch rather than about infliximab itself, the data consistently show that the biosimilars carry the same risk profile. The monitoring schedule stays the same regardless of which version you receive.